Insider Selling: United Therapeutics (NASDAQ:UTHR) EVP Sells 8,300 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul Mahon sold 8,300 shares of the stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $476.34, for a total value of $3,953,622.00. Following the completion of the transaction, the executive vice president owned 36,781 shares of the company’s stock, valued at approximately $17,520,261.54. This trade represents a 18.41% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

United Therapeutics Stock Up 0.9%

Shares of UTHR stock traded up $4.47 during mid-day trading on Thursday, reaching $480.52. 219,815 shares of the company’s stock traded hands, compared to its average volume of 330,249. The company’s 50-day moving average price is $485.84 and its 200-day moving average price is $437.55. The company has a market cap of $20.69 billion, a P/E ratio of 18.21, a P/E/G ratio of 2.57 and a beta of 0.85. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $519.99.

Institutional Trading of United Therapeutics

A number of large investors have recently added to or reduced their stakes in UTHR. Geneos Wealth Management Inc. lifted its position in United Therapeutics by 141.7% during the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 85 shares during the last quarter. Sequoia Financial Advisors LLC grew its position in United Therapeutics by 60.0% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 1,067 shares of the biotechnology company’s stock valued at $307,000 after acquiring an additional 400 shares during the last quarter. Nordea Investment Management AB increased its stake in United Therapeutics by 50.5% in the 2nd quarter. Nordea Investment Management AB now owns 10,914 shares of the biotechnology company’s stock worth $3,146,000 after buying an additional 3,664 shares during the period. DekaBank Deutsche Girozentrale raised its stake in shares of United Therapeutics by 0.4% during the second quarter. DekaBank Deutsche Girozentrale now owns 93,532 shares of the biotechnology company’s stock valued at $26,571,000 after acquiring an additional 367 shares in the last quarter. Finally, Brookstone Capital Management lifted its holdings in shares of United Therapeutics by 2.8% in the 2nd quarter. Brookstone Capital Management now owns 4,931 shares of the biotechnology company’s stock worth $1,417,000 after buying an additional 133 shares during the period. Institutional investors own 94.08% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. UBS Group reaffirmed a “buy” rating on shares of United Therapeutics in a report on Tuesday. Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a research report on Monday, December 29th. HC Wainwright lifted their target price on United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. Wells Fargo & Company boosted their target price on United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 30th. Finally, Royal Bank Of Canada raised their price target on shares of United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a report on Thursday, October 30th. Eight investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $509.50.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.